The DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
Open accessAbstract
Large observational data sets are a great asset to better understand the effects of medicines in clinical practice and, ultimately, improve patient care. For an empirical pattern in observational data to be of practical relevance, it should represent a substantial deviation from the null model. For the purpose of identifying such deviations, statistical significance tests are inadequate, as they do not on their own distinguish the magnitude of an effect from its data support. The observed-to-expected (OE) ratio on the other hand directly measures strength of association and is an intuitive basis to identify a range of patterns related to event rates, including pairwise associations, higher order interactions and temporal associations between events over time. It is sensitive to random fluctuations for rare events with low expected counts but statistical shrinkage can protect against spurious associations. Shrinkage OE ratios provide a simple but powerful framework for large-scale pattern discovery. In this article, we outline a range of patterns that are naturally viewed in terms of OE ratios and propose a straightforward and effective statistical shrinkage transformation that can be applied to any such ratio. The proposed approach retains emphasis on the practical relevance and transparency of highlighted patterns, while protecting against spurious associations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Visualisation of OE ratios over time, for the association in a collection of electronic patient records between first prescriptions of an antihypertensive medicine and diagnoses of swelling. The top panel displays the logarithm of the OE ratio (with shrinkage) over time. The bottom panel displays the underlying observed and expected numbers of events. Reproduced from Norén et al. [9] with permission from Springer.](/paper-figures/82c46f49c4f14c65b0205987ddb93d88/shrinkage-observed-to-expected-ratios-for-robust-and-transparent-large-scale-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimation with Quadratic Loss
James, W., & Stein, C. M. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-0919-5_30 · Cited by 2,319
Evans, S., WALLER, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,808
A Bayesian neural network method for adverse drug reaction signal generation
Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & Freitas, R. M. D. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,492
Self-citationDuMouchel, W. (1999) · The American Statistician · doi:10.1080/00031305.1999.10474456 · Cited by 883
Selecting the right interestingness measure for association patterns
Tan, P., Kumar, V., & Srivastava, J. (2002) · ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/775047.775053 · Cited by 868
ROTHMAN, K. J., GREENLAND, S., & WALKER, A. M. (1980) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113015 · Cited by 859 · cited 1×
“The additive baseline model has clear advantages as a basis for both individual decision-making and public policy-making.(13) Moreover, empirical results suggest that it is better suited to detect some patterns indicative of adverse drug interactions, at least in individual case safety reports.”
BackgroundLarge-Scale Bayesian Logistic Regression for Text Categorization
Genkin, A., Lewis, D. D., & Madigan, D. (2007) · Technometrics · doi:10.1198/004017007000000245 · Cited by 812
VigiBase, the WHO Global ICSR Database System: Basic Facts
Lindquist, M. (2008) · Drug Information Journal · doi:10.1177/009286150804200501 · Cited by 599
Sanz, E. J., Cuevas, C. D. L., Kiuru, A., Bate, A., & Edwards, R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17865-9 · Cited by 379
Self-citationProceedings of the Third Berkeley Symposium on Mathematical Statistics and Probability:
F., D. D., & Neyman, J. (1957) · Journal of the American Statistical Association · doi:10.2307/2280857 · Cited by 351
Cited by
Sorted by citations
Items 101–200 of 338
Zhang, Y., Fang, Y. V., Wu, J., Huang, G., Bin, J., Liao, Y., Shi, M., Liao, W., & Huang, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.817662 · Cited by 23
Zhai, Y., Ye, X., Hu, F., Xu, J., Guo, X., Lin, Z., Zhou, X., Guo, Z., Cao, Y., & He, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.767987 · Cited by 21
Grynblat, J., Khouri, C., Hlavaty, A., Jaïs, X., Savale, L., Chaumais, M., Kularatne, M., Jevnikar, M., Boucly, A., Antigny, F., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.02158-2023 · Cited by 21
Quantitative Signal Detection and Analysis in Pharmacovigilance
Bate, A., Pariente, A., Hauben, M., & Bégaud, B. (2014) · Wiley eBooks · doi:10.1002/9781118820186.ch20 · Cited by 20
Self-citationChen, Y., Ren, X., Dai, Y., & Wang, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-71977-0 · Cited by 21
COVID-19 Vaccination as a Trigger of IgA Vasculitis: A Global Pharmacovigilance Study
Ramdani, Y., Largeau, B., Jonville‐Béra, A. ‐., Maillot, F., & Audemard‐Verger, A. (2022) · The Journal of Rheumatology · doi:10.3899/jrheum.220629 · Cited by 20
Wang, F., Zhou, B., Sun, H., & Wu, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1170039 · Cited by 21
Fusaroli, M., Polizzi, S., Menestrina, L., Giunchi, V., Pellegrini, L., Raschi, E., Weintraub, D. A., Recanatini, M., Castellani, G., Ponti, F. D., et al. (2024) · Drug Safety · doi:10.1007/s40264-024-01471-z · Cited by 20
Appendicitis as a possible safety signal for the COVID-19 vaccines
Mitchell, J., & Yue, Q. (2021) · Vaccine X · doi:10.1016/j.jvacx.2021.100122 · Cited by 19
de Filippis, R., Cuevas, C. D. L., Sanz, E. J., Schoretsanitis, G., Correll, C. U., & de León, J. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.10.027 · Cited by 19
Cepaityte, D., Siafis, S., Egberts, T. C. G., Leucht, S., Kouvelas, D., & Papazisis, G. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa163 · Cited by 18
Park, J. K., Park, M., Kim, H. J., & Song, T. (2022) · Vaccines · doi:10.3390/vaccines10050799 · Cited by 19
Cuevas, C. D. L., Sanz, E. J., Ruan, C., & de León, J. (2022) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2021.07.005 · Cited by 18
Li, X., Zhang, L., Hu, S., Liu, D., Hu, B., Ran, J., Lin, X., Mao, W., & Hu, J. Y. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3098 · Cited by 19
Whalen, E., Hauben, M., & Bate, A. (2018) · Drug Safety · doi:10.1007/s40264-018-0640-8 · Cited by 18
Self-citationAcute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study
Zhu, J., Wu, J., Chen, P., You, K., Su, J., Gao, Z., Bi, Z., & Feng, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109350 · Cited by 18
Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study
Xia, S., Gong, H., Zhao, Y., Guo, L., Wang, Y., Zhang, B., Sarangdhar, M., Noguchi, Y., & Yan, M. (2022) · Cancers · doi:10.3390/cancers15010240 · Cited by 17
Cuevas, C. D. L., Sanz, E. J., Tezanos, A. G. V., & de León, J. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2192401 · Cited by 17
A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases
Zou, S., Ouyang, M., Zhao, Y., Cheng, Q., Shi, X., & Sun, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1392914 · Cited by 17
Juhlin, K., Star, K., & Norén, G. N. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4285 · Cited by 17
Self-citationLongitudinal medical records as a complement to routine drug safety signal analysis
Star, K., Watson, S., Sandberg, L., Johansson, J., & Edwards, I. R. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3739 · Cited by 17
Wei, L., Tian, Y., Chen, X., Guo, X., Chen, C., Zheng, Y., Xu, J., & Ye, X. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01514-4 · Cited by 17
Cuevas, C. D. L., Sanz, E. J., Jiménez‐Fernández, S., Schoretsanitis, G., Ruan, C., & de León, J. (2024) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-024-02623-3 · Cited by 18
Alami, A., Perez‐Lloret, S., & Mattison, D. R. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-087850 · Cited by 16
Egunsola, O., Star, K., Juhlin, K., Kardaun, S. H., Choonara, I., & Sammons, H. M. (2017) · BMJ Paediatrics Open · doi:10.1136/bmjpo-2017-000039 · Cited by 16
Cheminformatics-aided pharmacovigilance: application to Stevens-Johnson Syndrome
Low, Y., Caster, O., Bergvall, T., Fourches, D., Zang, X., Norén, G. N., Rusyn, I., Edwards, R., & Tropsha, A. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv127 · Cited by 17
Self-citationZhang, M., Xie, W., Li, J., Zheng, J., & Zhou, Y. (2023) · Archives of Women s Mental Health · doi:10.1007/s00737-023-01378-1 · Cited by 15
Xu, Y., Zhao, B., & Li-qun, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1438292 · Cited by 15
Montastruc, J., Rousseau, V., de Canecaude, C., Roussin, A., & Montastruc, F. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02913-0 · Cited by 15
Kim, J., Park, J., Min, Y. G., Hong, Y., & Song, T. (2022) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12507 · Cited by 15
Xia, S., Zhao, Y., Guo, L., Gong, H., Wang, Y., Ma, R., Zhang, B., Sheng, Y., Sarangdhar, M., Noguchi, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967017 · Cited by 15
Parkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiologic Study
Pacheco‐Paez, T., Montastruc, F., Rousseau, V., Chebane, L., Lapeyre‐Mestre, M., Renoux, C., & Montastruc, J. (2019) · Movement Disorders · doi:10.1002/mds.27876 · Cited by 15
Drug-induced antiphospholipid syndrome: Analysis of the WHO international database
Gérardin, C., Bihan, K., Salem, J., Khachatryan, H., Gerotziafas, G., Fain, O., & MEKINIAN, A. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103060 · Cited by 15
Wang, F., & Wu, X. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13707 · Cited by 14
Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis
Zhao, X., Wu, J., & Zhu, S. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15494 · Cited by 14
Zheng, Y., Guo, X., Chen, C., Chi, L., Guo, Z., Liang, J., Wei, L., Chen, X. T., Ye, X., & He, J. (2023) · Pharmaceuticals · doi:10.3390/ph16010098 · Cited by 14
Guo, L., Ma, J., Xiao, M., Liu, J., Hu, Z., Xia, S., Li, N., Yang, Y., Gong, H., Xi, Y., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06993-z · Cited by 15
Montelukast and Nightmares: Further Characterisation Using Data from VigiBase
Watson, S., Kaminsky, E., Taavola, H., Attalla, M., & Yue, Q. (2022) · Drug Safety · doi:10.1007/s40264-022-01183-2 · Cited by 14
Cuevas, C. D. L., Arrojo, M., Ruan, C., Schoretsanitis, G., Sanz, E. J., & de León, J. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2160318 · Cited by 14
Cuevas, C. D. L., Sanz, E. J., & de León, J. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2122813 · Cited by 13
Zhou, J., Wei, Z., Zheng, Y., Xie, H., Cao, W., Cai, X.-Y., Huang, J., & Wu, X. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2312 · Cited by 13
Fusaroli, M., Simonsen, A., Borrie, S. A., Low, D. M., Parola, A., Raschi, E., Poluzzi, E., & Fusaroli, R. (2023) · Journal of Speech Language and Hearing Research · doi:10.1044/2023_jslhr-22-00739 · Cited by 13
Pijnenburg, L., Salem, J., Lebrun‐Vignes, B., Sibilia, J., Javier, R., & Arnaud, L. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-0650 · Cited by 13
Liu, Y., Zhang, H., Jiang, Y., Wen, Z., Bao, E., Huang, J., Wang, C., Chen, C., Wang, J., & Yang, X. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.07.003 · Cited by 15
Yoon, S., Lee, S., Lee, K., Kim, J. S., Hwang, H. S., Kronbichler, A., Jacob, L., Shin, J., Lee, J. A., Park, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67020-x · Cited by 14
Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020
Rocca, E., Gauffin, O., Savage, R. L., Vidlin, S. H., & Grundmark, B. (2021) · Drug Safety · doi:10.1007/s40264-021-01091-x · Cited by 12
Cui, C., Zhang, S., Ren, X., Cui, W., & Wang, Y. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175561 · Cited by 11
Bahl, S., Taylor, P. N., Premawardhana, L. D., Stedman, M., Heald, A., Dayan, C. M., & Okosieme, O. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf449 · Cited by 11
“These ratios are based on the observed counts of AEs reported for a drug with respect to the expected count based on all other drugs in the database (27, 28).”
So, J. W., Bouibede, F., Jonville‐Béra, A. ‐., Maillot, F., Barbier, F., & Largeau, B. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13641 · Cited by 11
Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers
Karthikeyan, B., Sunder, S. S., Puzanov, I. J., Olejniczak, S. H., Pokharel, S., & Sharma, U. C. (2024) · Communications Medicine · doi:10.1038/s43856-024-00540-9 · Cited by 12
Fu, Z., Liu, J., Zhang, C., Hu, H., Li, S., Zhang, Y., & You, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1383212 · Cited by 11
Association of Pulmonary Hypertension With Trastuzumab Emtansine
Poisson, C., Hlavaty, A., Favrolt, N., Chaumais, M., Grynblat, J., Jutant, E., Lechartier, B., Maurac, A., Mouillot, P., Palat, S., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.11.006 · Cited by 11
Zhou, J., Wei, Z., Chen, S., Xie, H., Huang, W., Liu, M., & Wu, X. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15836 · Cited by 11
Barbieri, M. A., Russo, G., Sorbara, E. E., Cicala, G., Franchina, T., Santarpía, M., Speranza, D., Spina, E., & Silvestris, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1268672 · Cited by 11
Zhang, S., Yan, M., Zhao, H., Qiu, X., & Zhu, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1445324 · Cited by 10
Xu, S., Song, Z., Wang, D., Wang, E., & Wang, J. (2025) · BMC Cancer · doi:10.1186/s12885-025-14546-6 · Cited by 10
Park, J. M., Kim, D., & Song, T. (2022) · Vaccines · doi:10.3390/vaccines10060835 · Cited by 10
Kim, J., Park, J., & Song, T. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585221109397 · Cited by 11
Kim, J., Park, J. M., Min, Y. G., Hong, Y., & Song, T. (2022) · Muscle & Nerve · doi:10.1002/mus.27734 · Cited by 10
Safety surveillance of longitudinal databases: results on real‐world data
Norén, G. N., Hopstadius, J., Bate, A., & Edwards, I. R. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3258 · Cited by 10
Self-citationDan, H., Jiang, Q., Jia, X., Qi, G., Zong, D., & Li, Z. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1283807 · Cited by 9
Zhang, Y., Shan, C., Zhang, X., Liu, Y., Xia, Y., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1400101 · Cited by 9
Abulizi, A., Yan, G.-P., Xu, Q., Muhetaer, R., Wu, S., Abudukelimu, K., Chen, X., Liu, C., & Li, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-75099-5 · Cited by 9
Fusaroli, M., Mitchell, J., Rudolph, A., Rocca, E., & Fusaroli, R. (2025) · Drug Safety · doi:10.1007/s40264-025-01628-4 · Cited by 9
Madigan, D., & Shin, J. M. (2018) · Open Access Journal of Contraception · doi:10.2147/oajc.s161737 · Cited by 9
Zheng, Y., Guo, X., Chen, C., Chi, L., Guo, Z., Liang, J., Wei, L., Chen, X., Ye, X., & He, J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15535 · Cited by 9
Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19
Zou, J., & Jing, F. (2022) · Pharmaceuticals · doi:10.3390/ph15121472 · Cited by 10
Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors
Zhai, Y., Hu, F., Shi, W., Ye, X., Xu, J., Guo, X., Cao, Y., He, J., & Xu, F. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2204226 · Cited by 9
Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO’s VigiBase
Hirai, E., Haruki, T., Baba, T., & Miyazaki, D. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02573-3 · Cited by 9
Alami, A., Villeneuve, P. J., Farrell, P. J., Mattison, D. R., Farhat, N., Haddad, N., Wilson, K. R., Gravel, C. A., Crispo, J. A. G., Perez‐Lloret, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12154971 · Cited by 10
Chan, C. L., Rudrappa, S., Ang, P. S., Li, S. C., & Evans, S. J. W. (2017) · Drug Safety · doi:10.1007/s40264-017-0531-4 · Cited by 9
Can tramadol really induce hyponatraemia? A pharmacovigilance study
de Canecaude, C., Rousseau, V., Chebane, L., Lafaurie, M., Durrieu, G., & Montastruc, J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14401 · Cited by 9
Xia, S., Ma, J., Raschi, E., Ma, R., Zhang, B., Guo, L., Noguchi, Y., Sarangdhar, M., Gong, H., & Yan, M. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01308-0 · Cited by 9
Song, Z., Wang, Y., Liu, P., Geng, Y., Liu, N., Chen, J., & Yang, J. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00752-0 · Cited by 8
Zhao, Z., Yang, T., Wang, Y., Zhang, L., Li, J., & Su, Y. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16127 · Cited by 8
A shrinkage‐based comparative assessment of observed‐to‐expected disproportionality measures
Gipson, G. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2349 · Cited by 8
Hu, F., Ye, X., Zhai, Y., Xu, J., Guo, X., Guo, Z., Zhou, X., Ruan, Y., Zhuang, Y., & He, J. (2020) · Immunotherapy · doi:10.2217/imt-2019-0120 · Cited by 9
Therapeutic Opportunities for Intestinal Angioectasia‐ Targeting PPARγ and Oxidative Stress
Sarangdhar, M., Yacyshyn, M. B., Gruenzel, A. R., Engevik, M. A., Harris, N. L., Aronow, B. J., & Yacyshyn, B. (2020) · Clinical and Translational Science · doi:10.1111/cts.12899 · Cited by 8
Kamath, A., Acharya, S. D., Rao, R. R., & Ullal, S. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-98325-w · Cited by 8
de León, J., Cuevas, C. D. L., Sanz, E. J., & Verdoux, H. (2020) · Psychological Medicine · doi:10.1017/s0033291720001233 · Cited by 8
Nguyen, L. S., Raia, L., Lebrun‐Vignes, B., & Salem, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.619649 · Cited by 9
Balzano, N., Mascolo, A., Ruggiero, D., Rafaniello, C., Paolisso, G., Rossi, F., & Capuano, A. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241312497 · Cited by 8
Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
Niimura, T., Goda, M., Miyata, K., Matsumoto, J., Yoshioka, T., Hamano, H., Aizawa, F., Yagi, K., Izawa‐Ishizawa, Y., Zamami, Y., et al. (2023) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2023.1213771 · Cited by 7
Sartori, D., Aronson, J. K., Erlanson, N., Norén, G. N., & Onakpoya, I. (2024) · Drug Safety · doi:10.1007/s40264-024-01403-x · Cited by 7
Self-citationKeratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use
Aggarwal, P., Clark, D., Shah, A. M., Rismiller, K. P., & Neltner, S. A. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.0390 · Cited by 7
Ren, X., Wang, H., Deng, L., Wang, W., & Wang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112301 · Cited by 7
Wang, J., Ye, X., Guo, X., Zhu, T., Qi, N., Yong-fang, H., Zhang, T., Shi, W., Wei, X., Liu, Y., et al. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3811 · Cited by 7
Ryan, P. B. (2013) · Statistical Methods in Medical Research · doi:10.1177/0962280211403601 · Cited by 7
Lyu, Q., Ye, P., Zhang, H., Ye, X., Zheng, Y., Xu, J., Chen, X., Chen, C., & Guo, X. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15417 · Cited by 7
Largeau, B., Thoreau, B., Grangé, S., Jonville‐Béra, A. ‐., & Halimi, J. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13703 · Cited by 7
Russo, G., Barbieri, M. A., Sorbara, E. E., Cicala, G., Franchina, T., Santarpía, M., Silvestris, N., & Spina, E. (2023) · Biomedicines · doi:10.3390/biomedicines11082311 · Cited by 7
Evidence of Biological Mechanisms and Health Predictions: An Insight into Clinical Reasoning
Pérez‐González, S., & Rocca, E. (2022) · Perspectives in biology and medicine · doi:10.1353/pbm.2022.0005 · Cited by 7
Okada, N., Niimura, T., Saisyo, A., Kawaguchi, Y., Ishizawa, K., & Kitahara, T. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad414 · Cited by 6
Cheng, H. K., Lai, A., Kwok, M., Yan, B. P., & Poon, E. N.-Y. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01225-z · Cited by 6
Asano, H., Noguchi, Y., Kimura, M., Usami, E., & Yoshimura, T. (2023) · Medicina · doi:10.3390/medicina59111963 · Cited by 6
Kumar, N., Kalaiselvan, V., & Arora, M. K. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03727-0 · Cited by 6
Yang, C., Song, X., Sun, H., Chen, X., Liu, C., & Chen, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2390640 · Cited by 6
Sankar, C., Evans, S. J. W., Meyer, J. C., Gunter, H. M., Sekiti, V., & McCarthy, K. (2025) · Drug Safety · doi:10.1007/s40264-025-01547-4 · Cited by 5
A real-world population-based study on the association between cataracts and antipsychotics
Lakhani, M., Kwan, A. T. H., Chaudry, E., Popovic, M. M., Xie, J. S., Rai, A., Rai, A. S., Margolin, E., & McIntyre, R. S. (2025) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2025.05.021 · Cited by 6
Watson, S., & Härmark, L. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13617 · Cited by 6
Metadata
- Authors
- Norén, G. N., Hopstadius, J., & Bate, A.
- Affiliations
- Uppsala Monitoring Centre (SE)
- Corresponding author
- Norén, G Niklas
- Venue
- Statistical Methods in Medical Research
- Publisher
- SAGE Publications
- Published
- 2011-06-24
- Volume
- 22
- Issue
- 1
- Pages
- 57-69
- ISSN
- 0962-2802 (ISSN-L)
- 1477-0334
- PMC
- PMC6331976
- OpenAlex
- W2005366883
- Cited by
- 336
- References
- 26
- Citations by year
- 2026: 45 · 2025: 45 · 2024: 48 · 2023: 46 · 2022: 53 · 2021: 21 · 2020: 17 · 2019: 9 · 2018: 11 · 2017: 5 · 2016: 5 · 2015: 8 · 2014: 10 · 2013: 7 · 2012: 6
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Statistical Methods in Medical Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- observed-to-expected ratio, pattern discovery, observational data, spurious association, rare events, higher-order interactions, temporal association, associative strength, clinical practice
- MeSH terms
- Models, Statistical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review